GALT Earnings & Financial Statements
Galectin Therapeutics Inc.
$3.64
-$0.05(-1.36%)
42
Overall
40
Value
60
Tech
26
Quality
Market Cap
$367.90M
Volume
408.98K
52W Range
$2.03 - $7.13
Target Price
$11.00
GALT earnings and financial statements: Galectin Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
GALT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$20.09M | -$42.43M | -$38.07M | -$38.35M | -$30.18M |
| EBITDA | -$23.45M | -$41.47M | -$41.03M | -$37.71M | -$30.00M |
| Net income | -$30.84M | -$47.05M | -$41.07M | -$38.78M | -$30.53M |
| EPS (diluted) | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $19.53M | $17.50M | $28.20M | $21.29M | $41.83M |
| Total liabilities | $145.73M | $120.56M | $88.44M | $53.48M | $39.21M |
| Shareholders’ equity | -$127.92M | -$104.79M | -$61.96M | -$33.92M | $893.0K |
| Cash and equivalents | $17.70M | $15.12M | $25.66M | $18.59M | $39.65M |
| Long-term debt | - | $85.11M | - | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$23.90M | -$41.80M | -$33.00M | -$31.06M | -$24.31M |
| Free cash flow | -$23.90M | -$41.80M | -$33.00M | -$31.06M | -$24.31M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GALT | $3.64 | -1.4% | 408.98K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Galectin Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW